Company news
Rallybio Corporation news in 2023
Rallybio Corporation's news releases, calls and decks from 2023, newest first.
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
December 19, 2023
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
December 8, 2023
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
November 27, 2023
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 8, 2023
Rallybio to Present at Upcoming Investor Conferences in November
November 7, 2023
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
November 1, 2023
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
October 2, 2023
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
September 2, 2023
Rallybio to Present at Upcoming Investor Conferences in September
August 30, 2023
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 7, 2023
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
August 1, 2023
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
July 10, 2023
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
June 28, 2023
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
June 23, 2023
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
June 8, 2023
Rallybio to Present at the Jefferies Healthcare Conference
May 31, 2023
Rallybio Reports First Quarter 2023 Financial Results
May 8, 2023
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference
May 7, 2023
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis
April 5, 2023
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)
April 2, 2023
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
March 5, 2023
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
March 5, 2023
Rallybio to Present at Upcoming Investor Conferences in March
February 28, 2023
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy
February 26, 2023
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer
January 30, 2023
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023
January 4, 2023
Decks in 2023
- Corporate Update (December 2023)
Corporate update · 6 slides · Dec 20, 2023
- 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2023
Conference · 14 slides · Jun 24, 2023